The DOI matches its Crossref record.
Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Open accessAbstract
To evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon-α 2a (50 × 10 6 IU/m 2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11(31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by one third or one half because of persistent fatigue. Two patients with diabetes mellitus (one also had tabes dorsalis) exhibited mental deterioration that might have been partially attributable to interferon-α therapy. We conclude that interferon-α is useful in a proportion of Chinese patients with inoperable hepatocellular carcinoma, both in prolonging survival and in inducing tumor regression. (Hepatology 1993;17:389-394.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C. (2010) · Hepatology · doi:10.1002/hep.23485 · Cited by 473
Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., et al. (1998) · Hepatology · doi:10.1002/hep.510270529 · Cited by 467
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
Ryder, S. D. (2003) · Gut · doi:10.1136/gut.52.suppl_3.iii1 · Cited by 422
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
Simonetti, R. G., Liberati, A., Angiolini, C., & Pagliaro, L. (1997) · Annals of Oncology · doi:10.1023/a:1008285123736 · Cited by 380
Ikeda, K., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F., Tsubota, A., Chayama, K., Murashima, N., & Kumada, H. (2000) · Hepatology · doi:10.1053/jhep.2000.9409 · Cited by 354
Treatment of Hepatocellular Carcinoma
Bruix, J. (1997) · Hepatology · doi:10.1002/hep.510250201 · Cited by 277
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Recent advancements in the genetic engineering of microalgae
Sproles, A. E., Fields, F. J., Smalley, T. N., Le, C. H., Badary, A., & Mayfield, S. P. (2021) · Algal Research · doi:10.1016/j.algal.2020.102158 · Cited by 228
Metadata
- Authors
- Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J.
- Venue
- Hepatology
- Published
- 1993-03
- Volume
- 17
- Issue
- 3
- Pages
- 389-394
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2085664147
- Cited by
- 221
- References
- 0
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.